ILMN - Illumina - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4523271090

Sequencing Instruments, Genomic Analysis Kits, Whole-Genome Sequencing Kits

Illumina, Inc. is a leading provider of innovative solutions for genetic and genomic analysis, operating globally with a presence in the United States, Singapore, the United Kingdom, and other international markets. The company's business is divided into two main segments: Core Illumina and GRAIL.

The Core Illumina segment offers a range of sequencing and array-based instruments, consumables, and kits that enable researchers and clinicians to analyze genetic and genomic data. These products include reagents, flow cells, and library preparation tools, as well as whole-genome sequencing kits that can sequence entire genomes of varying size and complexity. Additionally, the company provides targeted resequencing kits that allow for the analysis of specific genes, RNA, or other genomic regions of interest.

Beyond its product offerings, Illumina also provides a range of services, including whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support. One of its flagship products is Galleri, a multi-cancer early detection test that has the potential to revolutionize cancer diagnosis. The company is also actively developing solutions to accelerate cancer diagnoses, detect minimal residual disease through blood-based testing, and support other post-diagnostic applications.

Illumina's customer base is diverse and includes genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through partnerships with life-science distributors.

Founded in 1998, Illumina is headquartered in San Diego, California, and has established itself as a pioneer in the field of genomics. With a strong commitment to innovation and customer support, the company continues to drive advancements in genetic and genomic analysis, ultimately improving human health and well-being.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for ILMN - Illumina  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for ILMN - Illumina  - Stock Price & Dividends

ILMN Stock Overview

Market Cap in USD 18,238m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Life Sciences Tools & Services
TER 0.00%
IPO / Inception 2000-07-28

ILMN Stock Ratings

Growth 5y -55.1
Fundamental 7.01
Dividend 0.00
Rel. Performance vs Sector -2.37
Analysts 3.71/5
Fair Price Momentum 98.37 USD
Fair Price DCF 60.40 USD

ILMN Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

ILMN Growth Ratios

Growth 12m -35.61%
Growth Correlation 12m -42%
Growth Correlation 3m 8%
CAGR 5y -16.42%
CAGR/Mean DD 5y -0.43
Sharpe Ratio 12m -0.98
Alpha vs SP500 12m -57.38
Beta vs SP500 5y weekly 1.06
ValueRay RSI 82.23
Volatility GJR Garch 1y 41.03%
Price / SMA 50 10.85%
Price / SMA 200 0.97%
Current Volume 1467.7k
Average Volume 20d 1828.8k

External Links for ILMN Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of ILMN stocks?
As of July 27, 2024, the stock is trading at USD 120.43 with a total of 1,467,725 shares traded.
Over the past week, the price has changed by +5.19%, over one month by +13.96%, over three months by +1.34% and over the past year by -35.51%.
What are the forecast for ILMN stock price target?
According to ValueRays Forecast Model, ILMN Illumina will be worth about 109.1 in July 2025. The stock is currently trading at 120.43. This means that the stock has a potential downside of -9.41%.
Issuer Forecast Upside
Wallstreet Target Price 142.3 18.2
Analysts Target Price 186.4 54.8
ValueRay Target Price 109.1 -9.41